Join the Fight Against MDS
Every gift helps patients, caregivers, and healthcare professionals access life-saving resources, support, and education. Together, we can make a difference. Even a small contribution can create a big impact. Thank you for your generosity.
December 4, 2020
Advances in Diagnosis & Management of MDS
Advances in Diagnosis & Management of MDS
Activity Overview
Dr. Bejar will examine current challenges in MDS diagnosis, including the use of molecular profiling and the diagnosis of clonal cytopenia of undetermined significance (CCUS). Dr. DeZern will describe her recent experience in managing MDS in the wake of a global pandemic. Dr. Götze will explore the potential of venetoclax in the treatment of higher-risk MDS. Dr. Gill will discuss the role of CAR-T cells in myeloid malignancies, focusing on what we learned from their use in lymphoid malignancies. Finally, Dr. de Botton will illustrate current perspectives in the use of targeted therapies in MDS patients, focusing on drugs that have already been approved for treatment of AML (enasidenib, ivosidenib) or that are currently in clinical trials on MDS (APR-246).
Agenda Topics
- Challenges in MDS diagnosis
- Managing MDS in the wake of a global pandemic
- Venetoclax in higher-risk MDS/AML
- Role of CAR-T cells in myeloid malignancies: lessons learned from lymphoid malignancies
- Targeted therapies (enasidenib, ivosidenib, APR-246)
Learning Objectives
- Describe molecular profiling in diagnostic and prognostic evaluation of MDS.
- Evaluate the impact of COVID-19 on management of MDS patients
- Utilize venetoclax in higher-risk MDS patients
- Identify the prospects of adoptive cellular immunotherapy modalities and novel transplant-related approaches in MDS
- Describe targeted therapies in MDS.
Cochairs
Mario Cazzola, MD
Jane Churpek, MD, MS
Stephen D. Nimer, MD
Speakers
Rafael Bejar, MD, PhD
Stephane de Botton, MD, PhD
Mario Cazzola, MD
Jane Churpek, MD, MS
Amy Elizabeth DeZern, MD, MHS
Saar Gill, MD, PhD
Katharina S. Gotze, MD
Stephen D. Nimer, MD
Outputs
Access to the meeting outputs are available below by clicking on each topic.
Our Supporters
Thank you to AbbVie, Astex Pharmaceuticals, Bristol-Myers Squibb, Daiichi Sankyo, Inc, Gamida Cell, Geron Corporation, and Onconova therapeutics for supporting this initiative.
